DDO-7263
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


DDO-7263
Description :
DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD) [1][2].CAS Number :
[2254004-96-9]UNSPSC :
12352005Target :
Keap1-Nrf2Type :
Reference compoundRelated Pathways :
NF-κBApplications :
COVID-19-immunoregulationField of Research :
Inflammation/Immunology; Neurological DiseaseAssay Protocol :
https://www.medchemexpress.com/ddo-7263.htmlPurity :
99.83Solubility :
DMSO : 17.86 mg/mL (ultrasonic; warming; heat to 60°C)Smiles :
CC1=NC=C(C2=NOC(C3=CC(F)=C(C=C3)F)=N2)C=C1Molecular Formula :
C14H9F2N3OMolecular Weight :
273.24References & Citations :
[1]Zhen Dai, et al. Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome. J Med Chem. 2022 Mar 24;65 (6) :5029-5043.|[2]Li-Li Xu, et al. 5- (3,4-Difluorophenyl) -3- (6-methylpyridin-3-yl) -1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic Biol Med. 2019 Apr;134:288-303.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development Reported

